The Multiple Myeloma Research Consortium (MMRC) Announces Oral and Poster Presentations at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting

NORWALK, Conn.--(BUSINESS WIRE)--May 31, 2012 - The Multiple Myeloma Research Consortium (MMRC) today announced four data presentations from multiple myeloma studies conducted through its clinical trial sites, in collaboration with industry partners, Bristol-Myers Squibb, Celgene, and Onyx at the 48th Annual American Society of Clinical Oncology (ASCO) Meeting June 1-5, 2012 in Chicago, IL.

On Sunday June 3rd Dr. Ravi Vij from Washington University in St. Louis and his MMRC collaborators will present “Pomalidomide with or without Low-dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes in Pts Refractory to Lenalidomide and/or Bortezomib” in an oral platform presentation. In a second oral presentation Dr. Andrzej Jakubowiak from the University of Chicago and his MMRC colleagues will present “Stringent Complete Response in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib, Lenalidomide, and Dexamethasone.” In addition, two poster presentations present data on trials evaluating investigational agents elotuzumab and carfilzomib in patients relapsed/refractory or intolerant to standard therapies.

“We are proud to be able to collaborate with our academic and industry partners to ensure that trials conducted within our consortium are advancing promising new treatments for multiple myeloma as rapidly and efficiently as possible” said Michael N. Needle, M.D., Chief Medical Officer of the Multiple Myeloma Research Foundation (MMRF) and MMRC.

The MMRC's clinical trials typically open approximately 60% faster than the industry standard in oncology and close ahead of projections due to targeted business solutions designed to advance drug development. The MMRC has facilitated the launch of 38 phase 1 and 2 clinical trials involving 21 investigational agents, two of which (carfilzomib and pomalidomide) are under marketing review by the U.S. Food and Drug Administration.

 

Abstract #:   8035
Title:   Response Rates to Single-agent Carfilzomib in Patients Refractory or Intolerant to both Bortezomib and Immunomodulators in Trial PX-171-003-A1

 

Lead Author:   David Samuel Dicapua Siegel
Session:   Poster Discussion Session (Board #15)
Date:   Saturday, June 2, 2012
Presentation Time:

 

  8:00 am - 12:00 pm CT and 12:00 - 1:00 pm CT
Abstract #:   8016
Title:   Pomalidomide (POM) with or without Low-dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Outcomes in Pts Refractory to Lenalidomide (LEN) and/or Bortezomib (BORT)

 

Lead Author:   Ravi Vij
Session:   Oral Abstract Session
Date:   Sunday, June 3, 2012
Presentation Time:   8:00 - 11:00 am CT
Abstract #:   8011
Title:   Stringent Complete Response (sCR) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX)

 

Lead Author:   Andrzej J. Jakubowiak
Session:   Oral Abstract Session
Date:   Sunday, June 3, 2012
Presentation Time:   8:00 - 11:00 am CT
Abstract #:   TPS8114
Title:   A Phase II Randomized Study of Bortezomib/Dexamethasone (Bort/Dex) with or without Elotuzumab (Elo) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RR MM) (CA204-009)

 

Lead Author:   Andrzej J. Jakubowiak
Session:   General Poster Session (Board #40G)
Date:   Monday, June 4, 2012
Presentation Time:   1:15 - 5:15 pm CT
About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $190 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator's coveted four star rating for nine consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit www.themmrf.org.

About the Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Mount Sinai School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University in St. Louis..

The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50294150&lang=en

 

 

Contact: Media:
Anne Quinn Young, MMRF
203-536-8691
QuinnYoungA@themmrf.org
or
Cara Amoroso, Feinstein Kean Healthcare
202-729-4013
Cara.Amoroso@fkhealth.com

 

 

Posted: May 2012

View comments

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web3)